Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The company uses iPS cells to develop treatments for diseases relating to the kidney
US Generics grew 5% to Rs. 467 Crores for the quarter
Subscribe To Our Newsletter & Stay Updated